Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

Feb 7, 2018

Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers

Jan 29, 2018

Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference

Jan 22, 2018

Cellectar Biosciences to Participate at Biotech Showcase 2018

Jan 4, 2018

Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers

Dec 14, 2017

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131

Dec 6, 2017

Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event

Nov 20, 2017

Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance

Nov 9, 2017

Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma

Nov 7, 2017

Cellectar Biosciences to Host Conference Call on November 10, 2017 to Report Third Quarter 2017 Financial Results and Corporate Performance

Nov 2, 2017